Osiris (NASDAQ:OSIR) is a stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care. They currently market and distribute Grafix and Ovation for acute and chronic wounds, Cartiform, a viable cartilage mesh for cartilage repair, and OvationOS, a viable bone matrix for bone growth.
The company reported that product revenue during the first quarter of 2014 was $10.1 million. The gross margin was 78%. However, we believe that both the product revenue and profit margin will take a huge hit in 2015 due to the loss of "Pass-Through" status. According to the new proposal that will be published by the Centers for Medicare & Medicaid Services (CMS) on July 14th, 2014, Grafix...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|